Autonomix Q2 FY2025 net loss $2.8M; PoC trial shows 100% of lead-in patients off opioids at 4-6 weeks

Autonomix Medical, Inc.

Net loss of $2.8M for three months ended Sept 30, 2024 vs $6.0M loss same quarter last year; cash $5.2M.
100% of lead-in responders zero opioid use at 4-6 weeks post-procedure; 83% pain reduction at follow-up.
60% enrollment reached in pancreatic cancer pain PoC trial; 79% responder rate with zero opioid use at 7 days.
Upcoming milestones: complete enrollment Q4 CY2024, topline data 1H 2025, FDA clearance targeted 1H 2027.
R&D expense $1.2M (vs $0.5M YoY) driven by clinical trial and product development costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.